Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Wusson Accelerator AB

Setback for pharmaceutical companies in the Zantac case

A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.

Tung patentutgång får Novartis att banta personalstyrkan

Novartis planerar att kapa bort 427 tjänster i USA, bland annat till följd av en kommande patentutgång för bolagets hjärtläkemedel Entresto.

From the sea of Åland to a self-test for lithium

Four years ago, a meeting on the sea of Åland resulted in the development of a self-test for lithium levels in the blood. The hopes are that the test will be av...

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

From lab to patient – the art of developing new antibody therapies

For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along ...

She creates pharmaceuticals on a 3D printer

The correct dosage for each individual, regardless of whether the pharmaceutical is for a seriously ill child or a frail elderly person, is the mission of a wel...

A growing industry in Denmark: “One new life science company a week”

The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage...

Business Sweden: “Companies have a lot to offer in data-driven precision medicine”

Data-driven precision medicine can potentially solve major healthcare problems, states Business Sweden in a new report on the subject.

Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients

In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Enhance your expertise with your measuring software

Discover the training options in our ZEISS Metrology Portal.

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.

WuXi AppTec, UK Ltd

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

Pfizer slutar sälja uppmärksammad genterapi

Pfizer kommer att avbryta utvecklingen och försäljningen av sin uppmärksammade och extremt dyra genterapi mot blödarsjuka, Beqvez. Orsaken uppges vara bristande efterfrågan.

BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

Conference recordings now available

Don't miss out on insights from leading experts.

List: The coolest names in biotech

Hairy beasts, volcanic material and space strolling stand out on a US list of the best biotech company names, and on a list of the coolest names for pharmaceuti...

Rickard Sandberg on this year’s Nobel Prize in Medicine: ”A key discovery”

The discovery that paved the way for the development of todays mRNA vaccines is the basis for this year’s Nobel Prize in Physiology or Medicine.